Orasis Pharmaceuticals Announces Novel Corrective Eyedrop for Presbyopia, Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%, Now Available to Prescribe in the U.S.

Qlosi’s proprietary EyeQ Formulation™ maximizes efficacy while minimizing side effects and offers patients flexible dosing – one or two drops a day – for up to eight hours of clear near vision

Ponte Vedra, FL, April 7, 2025 – Orasis Pharmaceuticals, an ophthalmic pharmaceutical company delivering solutions to reshape vision possibilities, today announced that Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%, a novel, corrective prescription eye drop for the treatment of presbyopia, or age-related blurry near vision, in adults is now available to prescribe in the U.S.

Qlosi’s proprietary EyeQ Formulation™ maximizes efficacy while minimizing side effects by balancing the lowest approved concentration of pilocarpine at a near neutral pH for optimal bioavailability, is preservative-free in single-use vials, and includes lubricants (HA & HPMC) for comfort. Patients have the flexibility of using one drop of Qlosi in each eye for improved near vision for a specific occasion or activity, and up to two drops per day for an extended effect, lasting up to eight hours.

“We are proud to deliver Qlosi, a solution that ushers in a new era in near vision correction and aims to empower patients, providing Qlosi Clear Moments through improved near vision,” said Elad Kedar, Chief Executive Officer of Orasis Pharmaceuticals. “Our goal has always been to improve near vision for the millions of people struggling with presbyopia, give them a break from readers, and provide eye care professionals with an additional option to optimize care for their patients.”

Read the full press release on the company’s website or view a PDF archive here.

Shared by Tyler Stowater, board member of Orasis Pharmaceuticals.